.png){kind=icon}
免疫肿瘤学& Immunotherapy
免疫肿瘤学（I / O）已成为一个重要的机会肿瘤学药物发现与发展。利用每个人独特的免疫系统的能力在一个有意义的肿瘤细胞的致命影响中产生了精密药物的爆炸。整合你的流式细胞术，efficacy models, imaging, biomarker, and伴侣诊断to quickly advance to the next milestone--because patients can't wait.
Make precision treatment a reality.
Access over 30 differentsyngeneic tumor models, from both solid and disseminated origins as well as access to commercially generatedhumanized mouse modelsor client-generated models.
Draw on over 1000 immuno-oncology clinical study experience in the last 10 years.
与A.合作肿瘤学CRO提供商谁在过去5年中为临床试验提供了近20,000名免疫肿瘤患者。
yaboapp体育官网临床前免疫疗法
It is essential to meaningfully assess the immune effector cells involved in the development of a particular tumor model and those involved in mediating the anti-tumor response of individual therapeutics. For many of our models, we havegrowth curves可用，我们继续使用抗CTLA-4，抗PDL-1和抗PD-1抗体的感兴趣的代理构建我们的数据库。
除了测试免疫调节剂本身或与免疫调节剂组合测试其他药剂之外，重要的是考虑造成的影响放射治疗，其与这些免疫肿瘤学协议组合融入和越来越多地研究。显示放射治疗和免疫调节剂的横向影响的数据以及直接组合的抗肿瘤效应，提供了概念的证据，并在临床前设置进一步调查这种高度使用的临床相关的模态。yaboapp体育官网
临床免疫肿瘤学
Making gains in precision medicine requires the use of novel methods to quickly test and target the right therapy to the right individual. At Covance, we have proven experience in immuno-oncology studies, including over 100 protocols in the past five years, performed in 58 countries at more than 2,860 sites with over 19,750 patients.
Our commitment to immuno-oncology is also evident through our support of more than 70% of allFDA-approved companion diagnostic products。作为最近关键阶段III注册试验的一部分，我们的中央实验室was the sole provider of testing for PD-L1 expression, which led to a new FDA-approved diagnostic test for OPDIVO®（Nivolumab）。此外，我们级别的伴随诊断功能支持Tagrisso的批准TM（Osimertinib）及其EGFR突变试验以及免疫疗法Keytruda®（Pembrolizumab）及其PD-L1伴侣诊断。
Immuno-oncology Educational Resources
无论您是在管道中的许多资产还是具有新兴产品组合的大型资产的大型制药公司，我们都有资源来帮助您在旅程中的每一部分。浏览我们的临床教育免疫肿瘤学资源，最能识别您的公司的管道：